Author:
Blackstock A W,Mornex F,Partensky C,Descos L,Case L D,Melin S A,Levine E A,Mishra G,Limentani S A,Kachnic L A,Tepper J E
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Allen AM, Zalupski MM, Robertson JM, Eckhauser FE, Simone D, Brown D, Hejna G, Normolle D, Lawrence TS, McGinn CJ (2004) Adjuvant therapy in pancreatic cancer: phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. Int J Radiat Oncol Biol Phys 59: 1461–1467
2. Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, Savage PD, Tepper JE (1999) Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17: 2208–2212
3. Blackstock AW, Lightfoot H, Case LD, Tepper JE, Mukherji SK, Mitchell BS, Swarts SG, Hess SM (2001) Tumor uptake and elimination of 2′,2′-difluoro-2′-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin Cancer Res 7: 3263–3268
4. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA (2004) Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 34: 107–116
5. Boven E, Schipper H, Erkelens CA, Hatty SA, Pinedo HM (1993) The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 68: 52–56
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献